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Abstract 
 
Purpose. To investigate microrobots as an assistive tool for minimally invasive intraocular surgery 
and to demonstrate mobility and controllability inside the living rabbit eye. 
Methods. A system for wireless magnetic control of untethered microrobots was developed. Mobility 
and controllability of a microrobot are examined in different media, specifically vitreous, balanced salt 
solution (BSS) and silicone oil. This is demonstrated through ex vivo and in vivo animal experiments. 
Results. The developed electromagnetic system enables precise control of magnetic microrobots over 
a workspace that covers the posterior eye segment. The system allows for rotation and translation of the 
microrobot in different media (vitreous, BSS, silicone oil) inside the eye. 
Conclusion. Intravitreal introduction of untethered mobile microrobots can enable suture-less and 
precise ophthalmic procedures. Ex vivo and in vivo experiments demonstrate that microrobots can be 
manipulated inside the eye. Potential applications are targeted drug-delivery for maculopathies such as 
age-related macular degeneration (AMD), intravenous deployment of anti-coagulation agents for retinal-
vein occlusion (RVO) and mechanical applications, such as manipulation of epiretinal membrane peeling 
(ERM). The technology has the potential to reduce the invasiveness of ophthalmic surgery and assist in 
the treatment of a variety of ophthalmic diseases. 
Keywords: Microrobot, intravitreal, minimally invasive surgery, magnetic, in vivo, vitreous, wireless, 
untethered 
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1. Introduction 
With the advent of modern ophthalmic devices such as 23 G and 25 G tools, ophthalmology is moving 
towards more minimally invasive surgery, resulting in less inflammation, decreased operating times 
and less damage to the conjunctiva 1. In order to further the advantages of minimally invasive 
ophthalmic surgery, several researchers are developing smart miniature tools or robot-assisted devices 
that assist in ocular surgery and help overcome the limits of human performance due to their high 
precision 2, 3, 4, 5, 6. Here we describe a microrobotic approach for minimally invasive surgery in the 
posterior eye segment as a future treatment for various ocular impairments and present results of in 
vivo mobility experiments of wirelessly controlled devices 285 µm diameter and 1800 µm length in 
lapine eyes. The small devices that we call “microrobots” are injected into the vitreous cavity through 
a small incision in the pars plana region of the sclera and can be guided wirelessly to the pathological 
site where they are operated by a surgeon to perform a required treatment such as mechanical 
manipulation or targeted drug delivery.   
The first use of a device of this type will be for directing intravitreal inserts near pathological 
sites on the retina in order to reduce the volume of drug required for treatment, thus extending the 
length of time for which the insert can provide a therapeutically relevant dose. While topical 
administration is most commonly used to treat ocular disorders, the physiological barriers to topical 
absorption are considerable. High administration frequency and high drug doses are required 7, 
because only a small fraction (approximately 1 to 10%) of the topically applied drug permeates the 
eye 8. Therefore, macular diseases are frequently administered by intravitreal injections, 
predominantly using anti-VEGF (vascular endothelial growth factor) agents 9. Intravitreal 
administration is superior to topical administration and systemic drug delivery, where toxic side 
effects to non-targeted tissue can occur due to high doses 7, 10.  
Intravitreal inserts are used for single injection, long-term drug delivery. These devices can be 
loaded with a variety of drugs targeting a broad range of ocular diseases. A pellet device comprising a 
silicone shell has been developed to release therapeutic intraocular doses of thalidomide and could be 
used for the treatment of subretinal neovascularization 11. Several non-bioerodible inserts have been 
suggested, which are loaded with ocular corticosteroid fluocinolone acetonide for the treatment of 
chronic, non-infectious uveitis, and have exhibited stable drug release over a period of approximately 
three months 11. OzurdexTM, a biodegradable intravitreal implant, is approved as a first-line treatment 
for RVO 12. These ocular inserts lack the ability to move and, therefore, cannot be safely directed to a 
pathological site within the eye. Additionally, the removal of some of these devices requires a 
vitrectomy, which bears risks of complications. The addition of mobility to intravitreal devices to 
guide them to the diseased area will allow much slower release drug delivery while providing an 
equivalent dosage to the pathology due to the nonlinear nature of Fick’s law of diffusion.  
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In addition to guiding intravitreal inserts, other mechanical operations inside the vitreous 
cavity may also be performed in the future. Pars plana vitrectomy can successfully treat retinal 
detachments, macular-hole formation, vitreo-macular traction syndromes, retinal vein occlusion 
(RVO), proliferative DR, vitreous hemorrhages, and diabetic macular edema (DME) by epiretinal 
membrane (ERM) peeling 13. The delicate structure of the retina is at risk during surgery due to a lack 
of tactile information arising from the limits of human force perception 14, 15. Ophthalmic surgery is 
mechanically difficult and may lead to complications such as cataract, vitreous cavity hemorrhage or 
retinal detachment 16, 17. 
 Microrobots are a new wireless tool for future suture-less ocular surgery and are rapidly 
gaining interest as in vivo diagnostic and therapeutic devices 18, 19, 20. In order to utilize these 
microrobots in future ophthalmic applications such as ERM, localized drug delivery or puncturing 
retinal veins, they must exhibit biocompatibility, mechanical stability, hypoallergenic, non-
carcinogenic, and chemically inert properties 11. Furthermore, the technology must allow the surgeon 
to precisely control rotation and translation of the microrobot inside the vitreous. This work 
investigates the mobility of intraocular microrobots as potential tools for microsurgery. The aim is to 
understand robot mobility in the posterior eye segment in vitreous humor as well as after replacement 
of the vitreous with different media. This paper utilizes an electromagnetic system capable of 
dexterous micromanipulation of steerable magnetic intraocular microrobots. Mobility and control of 
these microrobots are successfully demonstrated in vivo. Microrobots can be removed in a controllable 
and minimally invasive manner, potentially avoiding a vitrectomy, and, thus making ophthalmic 
surgical interventions accessible to a larger set of ophthalmic surgeons and more acceptable by 
patients.  
2. Materials and Methods 
2.1. Intraocular Microrobot 
Figure 1(a) shows a microrobot, which is injected, into the posterior section of the eye through the 
pars plana region of the sclera. The microrobot is wirelessly controlled and can be removed by a 
magnetic tool. The soft-magnetic microrobot has the shape of a hollow cylinder with outer diameter of 
285 µm and inner diameter of 125 µm; its length is 1800 µm. The outer diameter is chosen such that 
the microrobot fits a 23 G needle, as shown in Figure 1(b). The microrobot is rendered non-toxic using 
polypyrrole or inert metallic coatings, which have been tested for cell viability by Sivaraman et al. 21 
and customized fabrication methods allow for high flexibility in diameter, length and magnetic 
volume 21, 22. 
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Figure 1: (a) Cylindrical microrobot with outer diameter of 285 µm, inner diameter of 125 µm and length 
of 1800 µm. (b) A microrobot in a 23 G needle 
2.2. OctoMag: An Electromagnetic System for Magnetic Microrobot Control 
The OctoMag, an electromagnetic system that allows for unrestrained wireless electromagnetic control, 
was introduced by Kummer et al. 23. The OctoMag is capable of controlling magnetic devices in three 
dimensions (3D). The workspace of this magnetic system is approximately 20 mm x 20 mm x 20 mm 
and covers the posterior segment of the human eye, which has a an approximate diameter of 
20 mm 24, 25. The OctoMag consists of eight electromagnets arranged in a hemispherical configuration. 
The electromagnets are operated with direct currents and are equipped with soft-magnetic cores, and 
can generate an electromagnetic field of up to 40 mT with gradients up to 1T/m. The rotation of a 
microrobot is controlled by the orientation of the applied magnetic field, whereas the magnitude of the 
force applied to the microrobot is a function of the field gradient. The current system, shown in Figure 
2, can accommodate a small animal (e.g. rabbit) for in vivo experiments. 
 In ex vivo experiments a Leica M80 stereomicroscope [Leica Microsystems, Switzerland] 
equipped with a Grasshopper 03K2C-C camera [Pointgrey, British Columbia, Canada] and a wide 
field enhanced BIOM lens [WFE 53602, Oculus, Germany] for non-contact 120° wide-angle 
observation views the workspace from above. The microscope has an objective lens (f = 200 mm) 
from the Leica retinal surgery series. For in vivo experiments a Leica Wild series microscope equipped 
with the same Grasshopper camera is used to observe the workspace from above. To minimize the 
reflections from the optical interface a disposable planoconcave vitrectomy contact lens [S5-7010u, 
FCI Ophthalmics, USA] is placed on the eye. 
a)# b)#
1#mm#
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Figure 2: OctoMag, utilizing eight electromagnets for wireless magnetic microrobot control. A surgical 
microscope and a BIOM allow for observation from above.  
2.3. Porcine Eyes (ex vivo) 
It has been suggested that the viscoelastic behavior of the central vitreous region of a pig closely 
resembles that of the central vitreous region of a human eye in terms of rheological parameters 26. The 
same study reports that the anterior and posterior regions of the porcine vitreous resemble a dense gel, 
whereas the human vitreous has a thinner and in some cases aqueous consistency. Similarly, it has 
been observed, that human vitreous undergoes liquefaction with increasing age 27. It can be concluded 
that, with respect to the properties of the vitreous humor, porcine eyes act as a stiff model of the 
human eye. 
 In order to account for the rapid loss of hyaluronic acid of the vitreous upon removal from the 
eye globe and to sustain the intraocular pressure (IOP), microrobotic mobility experiments are 
conducted inside the eye globe without destroying the natural structure of the eye. Ex vivo experiments 
in porcine cadaver eyes are performed one hour post mortem. 
2.4. Lapine Eyes (in vivo) 
In order to evaluate the ability of intravitreal microrobots to move in the living eye, in vivo mobility 
experiments were conducted in rabbits. Due to their characteristic bright red eyes, the New Zealand 
white rabbit breed (9 month-old females) was chosen for this study. Experiments are undertaken in 
five individual rabbit eyes, three of which are vitrectomized. One eye is subsequently filled with BSS 
and two with silicone oil (AK 1000). The rabbit is anesthetized and its head is placed inside the 
workspace of the OctoMag, such that the studied eye is located in its center, as illustrated in Figure 3. 
 The protocols concerning animal housing, treatment and monitoring were approved by the 
Swiss Veterinary Office according to the Swiss decree on animal protection 28 and adhere to the 
ARVO guidelines for animal experiments. This study was undertaken in cooperation with 
ophthalmologists from the University Hospital Bern and the Veterinary Hospital Zurich. 
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Figure 3: Anesthetized rabbit placed with the studied eye centrally in the OctoMag workspace 
2.5. Mobility Experiments 
A microrobot is injected into the central vitreous humor of the porcine or lapine eyes with a syringe 
equipped with a 23 G needle. After insertion of the microrobot, the eye is placed centrally in the 
workspace of the OctoMag for experimentation. After experimentation the microdevice is removed 
from the vitreous cavity using a magnetic tool that is manufactured from a standard syringe. A 
magnetic wire is inserted into the needle, which attracts the microrobot if a low magnetic field is 
applied that also orients the device. Subsequently, the microrobot can be pulled into the needle and 
removed from the eye. Injection and removal of an intraocular microrobot are illustrated in Figure 4. 
 
 
Figure 4: a) Schematic of an eye with transscleral illumination and injected robot. b) Removal of 
intravitreal microrobot using a magnetic tool. A weak magnetic field is applied to orient the microrobot.  
2.5.1. Rotational Mobility 
The intraocular microrobot is rotated in the plane, normal to the line of vision in the posterior region 
of the eye. The rotation of the microrobot is caused by the rotation of the applied magnetic field, 
Magne&c(tool(
microrobot(
Eye(
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which is generated by the OctoMag. The microrobot rotational mobility is examined in lapine vitreous, 
BSS and silicone oil in vivo and in porcine vitreous ex vivo. 
In order to evaluate the rotational mobility of an untethered intraocular microrobot and its 
response to magnetic field strength, the field magnitude is set to 10 mT, 20 mT, 30 mT and 40 mT 
whereas the field’s rotational frequency is held constant at 1 Hz and the intraocular microrobot 
mobility is recorded. In a second series of experiments, the rotation of an intraocular microrobot is 
investigated at constant field magnitude whereas the field rotation frequency is set to 0.05 Hz, 0.1 Hz, 
0.5 Hz, 1 Hz and 2 Hz. For experiments in vitreous and silicone oil the field magnitude is held 
constant at 30 mT. It is set to a lower field magnitude (10 mT) for experiments in BSS due to an 
unstable response of the microrobot in BSS at higher field strengths.  
2.5.2. Translational Mobility 
In order to examine the translational mobility of the microrobot inside the eye globe, a magnetic 
gradient is applied. The microrobot is surrounded by lapine vitreous, BSS or silicone oil in in vivo 
experiments and porcine vitreous in ex vivo testing. The magnetic field gradient is increased from 0 to 
500 mT/m, resulting in translational movement of the intraocular microrobot whereas the field 
magnitude and orientation are held constant for each experiment. Experiments are undertaken for 
magnetic field magnitudes of 10 mT, 20 mT, 30 mT and 40 mT. Furthermore, the translational 
mobility of the microdevice in porcine and lapine vitreous is compared. 
2.5.3. Motion Tracking 
The microscope equipped with a camera takes consecutive images of the inside of the eye globe with a 
speed of 15 Hz. In order to track the microrobot movement a script is written in MATLAB, which 
returns the robot orientation and position in every image. Due to minor movement of the rabbit eye 
during in vivo experiments, noise occurs and the microrobot position data must be filtered using a 
moving average filter with window size of ten data points for further analysis. 
3. Results and Discussion 
3.1. Rotational Movement 
As a result of the rotating magnetic field, the intraocular microrobot follows the field with a time delay. 
Figure 5 a) indicates the angle of rotation of the magnetic field, 𝛼!"#$%, and the angle of rotation of the 
microrobot, 𝛼!"#"$. The response of the robot to a 10 mT field rotating counter clockwise with 
frequency of 0.5 Hz is illustrated in Figure 5 b). A black arrow indicates the orientation of the 
magnetic field. 
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Figure 5: a) Inertial coordinate frame, where the x-y plane is perpendicular to the line of vision. b) A gold-
coated intravitreal microrobot inside the vitreous of a live rabbit. As the applied magnetic field (indicated 
by a black arrow) rotates anti-clockwise, the microrobot follows with a time delay.  
3.1.1. Constant Magnetic Field Frequency 
Figure 6 graphs the angle of rotation of an applied magnetic field at various field magnitudes, rotating 
at 1 Hz, and the rotation of a microrobot inside the eye over time, where T is the period of rotation in 
seconds (T = 1 s). Figure 6 a) illustrates microrobot rotation in lapine vitreous (in vivo), subfigures b) 
and c) show the microrobot movement in BSS and silicone oil (in vivo), respectively. Figure 6 d) 
shows the rotational motion of the microrobot in porcine vitreous (ex vivo). The black arrow indicates 
the time delay between the rotating field and the microrobot rotation.  
 It is observed that the plotted angles of rotation show almost no change for different field 
magnitudes in all four surrounding media. The time delay of the microrobot rotation compared to the 
field rotation is similar for all recorded field magnitudes at constant frequency in each medium. 
Therefore, it is concluded that the magnitude of the rotating magnetic field has no influence on the 
time delay of the microrobot. Unlike in vitreous, the microrobot shows very unstable movement in 
BSS at 40 mT (not plotted). This instability of the microrobot can be explained with an increasing 
magnetic drift inside the OctoMag workspace due to the increasing field strength. Furthermore, the 
viscosity of BSS is much lower than that of vitreous, thus, less damping of the movement is observed 
and instabilities are less controllable. In porcine vitreous the microrobot movement is hindered at field 
strength of 10 mT (not plotted), presumably due to collagen fibers inside the vitreous. 
a)# b)#
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t#=#0#s# t#=#0.13#s# t#=#0.27#s#
t#=#0.4#s# t#=#0.53#s# t#=#0.67#s#
Magne6c#ﬁeld#
vector#
y
x#
αrobot#
αﬁeld#
 10 
 
Figure 6: Angle of rotation of the applied magnetic field (rotation frequency 1 Hz) and the microrobot a) 
in lapine vitreous (in vivo), b) inside the lapine eye in BSS (in vivo), c) inside the lapine eye in silicone oil 
(in vivo), d) porcine vitreous (ex vivo) at field magnitudes 10 mT, 20 mT, 30 mT, 40 mT 
3.1.2. Constant Magnetic Field Magnitude 
Figure 7 illustrates the angle of rotation of the rotating magnetic field and the intraocular microrobot 
surrounded by a) lapine vitreous, b) BSS, c) silicone oil and d) porcine vitreous. The rotation is plotted 
against time, where T is the period of rotation at a corresponding frequency. It is observed, that the 
relative time delay between the field angle of rotation and the microrobot rotation increases with 
decreasing period T, and thus increasing field frequency. It is concluded that the time delay between 
robot rotation and the rotating magnetic field corresponds to rotational field frequency. Furthermore, it 
is observed that the time delay between angle of rotation of the field and the microrobot is generally 
larger in vitreous (lapine and porcine) than in BSS and silicone oil. This observation is attributed to the 
presence of elastic collagen fibers in vitreous. 
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Figure 7: Angle of rotation of the applied magnetic field and the microrobot at frequencies 0.05 Hz, 
0.1 Hz, 0.5 Hz, 1 Hz, 2 Hz, in a) lapine vitreous (in vivo; 30 mT), b) BSS (in vivo 10 mT) c) silicone oil (in 
vivo; 30 mT), d) porcine vitreous (ex vivo; 30 mT) 
 As suggested in literature vitreous is not only a viscous fluid, but also has elastic properties 29, 
which are observed in some experiments described in this work. Figure 8 shows the corresponding 
plots for such a case, where the microrobot is unable to accomplish a full rotation due to being caught 
in collagen fibers. The figure shows an applied magnetic field rotating at a frequency of 0.5 Hz with a 
magnitude of 30 mT. Figure 9 illustrates consecutive images of this motion behavior of the microrobot. 
Images a) to d) show the intravitreal microrobot at a constant orientation whereas the magnetic field, 
indicated by a black arrow, changes its angle. When the angle between the magnetic field and the 
microrobot becomes larger than 90°, the microrobot quickly aligns with the field and, subsequently, 
starts following the field with a delay until it pauses again. Using a microscope, thin collagen fiber 
bundles can be observed that are attached to the intravitreal microrobot. Therefore, it is concluded, that 
the insert is entangled in the elastic fibers, which constrain the microrobot mobility in vitreous. 
 
Figure 8: Angle of rotation of the applied magnetic field (10 mT) and the microrobot in lapine vitreous (in 
vivo) at field rotation frequency 0.5 Hz 
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Figure 9: Microrobot in lapine vitreous. In a) to d) the microrobot maintains the same orientation, while 
the field (indicated by a black arrow) changes orientation. When a large difference is reached (>90°), the 
robot quickly follows the field e) and starts rotating as normally d). 
 In order to compare the mobility of an intraocular microrobot in different media, Figure 10 
summarizes the correlation between the relative time delay of a microrobot in lapine and porcine 
vitreous, BSS and silicone oil, and the rotation of the magnetic field. The relative delay, defined by the 
time delay normalized by the period of rotation, is plotted against the period and its frequency in the 
surrounding media. The figure illustrates that relative time delay decreases with decreasing frequency 
and thus, increasing period T. 
 
Figure 10: Ratio between the time delay of the microdevice to the field rotation and the period of the field 
rotation T, plotted against the period of the field rotation in seconds. 
3.2. Translational Movement 
The force resulting in the translation of the intraocular microrobot is caused by an applied magnetic 
field gradient generated by the OctoMag. Figure 11 shows four consecutive images of a wireless 
microrobot inside the vitrectomized rabbit eye, surrounded by BSS. A magnetic field gradient is 
applied along the horizontal direction causing the microrobot to translate along this axis. 
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Figure 11: Wireless microrobot inside the vitrectomized (in vivo) rabbit eye surrounded by BSS. A 
magnetic field gradient is applied causing the microrobot to translate. 
 Figure 12 illustrates translational movement of a microrobot in lapine vitreous. The red line 
shows the position of the microrobot as a result of an increasing gradient along the axis of robot 
orientation at constant field magnitude (20 mT). A general increase of translation due to increasing 
field gradient is observed. However, the translation of the microrobot in vitreous is less than 0.2 mm 
for a magnetic gradient, that increases piecewise from 0 to 500 mT/m over 20 seconds, as seen in 
Figure 12. It is assumed that collagen fiber bundles that attach to the microrobot in vitreous cause the 
lack of translational movement. The interaction between the microrobot and collagen fiber bundles can 
be modeled as a mass-spring system. Figure 13 shows the response of a microrobot that is entangled in 
a collagen fiber bundle within lapine vitreous. Magnetic gradients between 0 and 300 mT/m are 
applied at a constant field magnitude of 30 mT. It is shown that the applied force is proportional to 
microrobot displacement. Thus, collagen fiber bundles show the behavior of a linear spring. 
 
 
Figure 12: Translation of intravitreal microdevice due to magnetic field gradient at a constant field of 
20 mT in lapine vitreous (in vivo) 
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Figure 13: Translational movement of intravitreal microrobot that is entangled in collagen fiber bundle at 
30 mT. The applied magnetic gradient is directly proportional to the displacement of the microrobot. The 
microrobot that is attached to a collagen fiber bundle can be modeled as a spring-mass system. 
Figure 14 illustrates the behavior of the microrobot in BSS inside the living rabbit eye. The 
red line shows the position of the microrobot within the eye, whereas the green dashed line indicates 
the increasing field gradient. Similar to in vivo experiments in vitreous, the general trend shows 
increasing translation for increasing magnetic field gradients. The translation of the microrobot in BSS 
is an order of magnitude larger than in lapine vitreous with a maximum of 4 mm. As stated before, 
BSS is less viscous than vitreous, thus, allowing for better mobility of the microrobot. Furthermore, no 
collagen fibers are present in BSS in that the microrobot can entangle. However, due to the low 
viscosity of BSS, the microrobot sinks to the retina instead of floating within the central eye. When 
applying a magnetic field gradient, the microrobot sticks to the retina until a critical gradient is applied 
that generates a force, which is large enough to overcome friction. The black arrow in Figure 14 
indicates a characteristic stick-slip friction behavior of the microdevice in BSS. In the in vivo 
experiment the device starts to translate at this critical field gradient (420 mT/m), as illustrated in the 
figure. 
 
Figure 14: Translation of microdevice due to magnetic field gradient at a constant field of 30 mT in BSS 
inside the vitrectomized lapine eye (in vivo); the critical gradient is indicated by the black arrow. 
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Figure 15 illustrates the microrobot response to various gradients at a constant field magnitude 
(20 mT) in porcine vitreous. It is observed, that an increasing field gradient results in an increased 
translation of the microrobot. Furthermore, a typical viscoelastic behavior of the vitreous is observed. 
By applying a constant gradient, a constant force is exerted on the device. However, the translational 
movement of the microdevice shows a delayed creep response to the force input. At a field magnitude 
of 20 mT the maximum translation of the robot is measured to be 3.2 mm in porcine vitreous. The 
resulting maximal translational displacements of an intraocular microrobot in porcine vitreous as a 
result of changing field gradients are summarized in Table 1. The table shows that the translational 
displacement increases with increasing magnetic gradient, as well as increasing field magnitude. 
However, the gradient generally has a larger influence on the translational behavior of the intravitreal 
microdevice. 
 
Figure 15: Translation of intravitreal microdevice due to magnetic field gradient at a constant field of 
20 mT in porcine vitreous (ex vivo) 
 
Table 1: Maximal translational displacement in mm due to magnetic gradient [mT/m] at constant field 
magnitude [mT] in porcine vitreous (ex vivo) 
 
              Gradient 
Field mag. 100 mT/m 200 mT/m 300 mT/m 400 mT/m 500 mT/m 
10 mT 0.2 0.6 1.1 1.4 1.7 
20 mT 0.5 1.6 1.5 2.7 3.2 
30 mT 1.1 1.5 2.4 3.0 3.0 
40 mT 1.3 2.2 2.4 - - 
When comparing results from the in vivo experiments in lapine vitreous with those from ex vivo 
experiments in porcine vitreous, it is observed that translational displacement of the intravitreal 
microdevice is approximately one order of magnitude larger in porcine vitreous. 
Furthermore, none of the rabbit eyes under observation showed immediate inflammation during the 
experiments or upon removal of the microrobot. 
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4. Conclusion 
This work demonstrates the general feasibility of controlling the movement of a wireless microdevice 
inside the eye. As the microrobot can be injected into the eye, steered and removed from the vitreous 
cavity by a surgeon, this technology potentially offers the possibility to assist in minimally invasive 
ophthalmic treatments. Future applications include localized slow-release targeted drug delivery and 
assistance in mechanical operations inside the eye. 
 Lapine in vivo and porcine ex vivo experiments show that a microdevice can be injected into 
the vitreous cavity, filled with vitreous, BSS or silicone oil, and moved inside the vitreous cavity. 
Rotational as well as translational mobility of the microdevice have been explored. It is shown that the 
microrobot rotation is similar in the four surrounding media investigated, only being dependent on the 
rotational frequency of the applied magnetic field. Thus, a surgeon using this technology has better 
control over the intraocular microrobot at low rotation frequencies and low field magnitudes due to 
decreased instabilities and magnetic drift. Microrobot translation depends on the applied field gradient 
and the viscosity and elasticity of the surrounding medium. In the experiments, vitreous exhibits a 
viscoelastic behavior, and the microdevice can get caught in bundles of collagen fibers, which reveal 
spring like characteristics. The experiments show that the microrobot has increased translational 
mobility in cadaver porcine vitreous compared to living lapine vitreous. Reasons for this observation 
are higher density of rabbit vitreous and the post mortem liquefaction 27 of the vitreous in the cadaver 
pig eyes.  
 For future purposes the microrobot can be microfabricated with specific designs. The size as 
well as the shape of the microrobot can be adjusted to the task. For slow-release targeted drug delivery 
the microrobot features a drug reservoir, whereas mechanical components, such as needles or hooks, 
are attached for mechanical applications. The microrobot dimensions are only restricted by the inner 
diameter of a 23 G needle, which is used for suture-less injection through the pars plana region of the 
sclera into the eye. The electromagnetic control system, OctoMag, allows for precise control of the 
microrobot in 3D by generation of an oriented magnetic field and gradient. The risk of ophthalmic 
surgery can potentially be reduced to a minimum with the assistance of minimally invasive 
microrobots. Changes in position, which are beyond human perception, can be tracked with high 
resolution by the surgeon during an operation. Additionally, the forces applied to the robot can be 
derived from the system inputs. Moreover, the absence of human tremor reduces the risk of damaging 
the delicate structures in the eye. 
 Ongoing research focuses on future applications of microrobots inside the eye globe, 
especially assistance in the treatment of maculopathies, such as AMD, intravenous deployment of anti-
coagulation agents for RVO and mechanical applications, like epiretinal membrane peeling. 
Additionally, we focus on minimally invasive removal of a microrobot and tissue material from the 
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ocular globe. Furthermore, current research addresses the development of coatings to minimize 
adhesion between the microrobot and collagen fibers in the vitreous. Further studies on the 
biocompatibility of intravitreal microrobots are currently ongoing. 
 To summarize, this work investigates microrobots as a tool for minimally invasive intraocular 
surgery and demonstrates the mobility of a microrobot inside the living eye, surrounded by vitreous, 
BSS and silicone oil. Rotational as well as translational mobility of the microrobot have been 
investigated and the potential of an intravitreal microrobot assisting in surgery inside the eye, such as 
targeted drug delivery or mechanical applications, is examined. Microrobots can augment the 
capabilities of ophthalmic surgeons and aid them in achieving safer and more precise interventions 
with reduced recovery times for the patient. As a result, they can be considered a compelling assistive 
technology for ophthalmic surgery. 
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